包氏免疫性肾小球肾炎;COVID-19感染的晚期并发症

H. Waseem, F. Zafar, M. Anser, M. Zia
{"title":"包氏免疫性肾小球肾炎;COVID-19感染的晚期并发症","authors":"H. Waseem, F. Zafar, M. Anser, M. Zia","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A4089","DOIUrl":null,"url":null,"abstract":"Introduction: Coronavirus disease is a multi-organ disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2). Although acute kidney injury, collapsing glomerulopathy and thrombotic micro-angiopathy have been frequently attributed to COVID-19, pauci-immune glomerulonephritis (GN) has rarely been described [1]. Here we report a case of pauci-immune GN associated with SARS-CoV-2. Case Presentation: A 53 years old female with hypertension, diabetes mellitus, hepatitis C (treated 6 years ago), and recent covid-19 pneumonia (3 months ago), presented with dysuria, nausea, and vomiting. She denied fever, flank pain, and hematuria. The laboratory workup showed elevated blood urea nitrogen BUN 82 mg/dl and creatinine Cr 9.8 mg/dl (baseline creatinine was 0.9 mg/dl three months ago). Urinalysis showed proteinuria >1000 mg/dl and urine protein creatinine ratio of 5.3 (normal < 0.1), concerning for glomerulonephritis. Serological evaluation for glomerular disease showed normal complements C3 and C4, normal titers of anti-neutrophil cytoplasmic antibodies including p-ANCA, c-ANCA, atypical ANCA, and cryoglobulins. Screening for Hepatitis B and Hepatitis C was negative. The remainder of the autoimmune workup was unremarkable including Rheumatoid factor, Anti CCP antibodies (Ab), Anti Ribo-nucleoprotein Ab, and Anti Glomerular basement membrane antibodies. Coronavirus PCR was negative and qualitative IgG was reactive. CT chest showed idiopathic pulmonary fibrosis (IPF) and resolving ground glass opacities from prior coronavirus infection. CT abdomen and pelvis was unremarkable for obstructive uropathy. The renal biopsy showed pauci-immune focal sclerosis with 20% fibro-cellular crescents diagnostic for pauci-immune glomerulonephritis. The patient was treated for pauci-immune glomerulonephritis with pulse-dose intravenous steroids (methylprednisolone) followed by oral prednisone and rituximab. The renal functions improved dramatically (on day 15, her creatinine down-trended to 4 mg/dl from 9mg/dl on admission). She did not require intermittent hemodialysis and was discharged on day 15 with outpatient follow up. Discussion: The mechanisms of acute kidney injury in COVID-19 include renal hypoperfusion, endothelial dysfunction, micro-thrombi, and cytopathic effects of SARS-CoV-2 towards renal tubules and glomeruli. Due to a lack of scientific evidence related to coronavirus disease, the management of glomerulopathy is challenging. The existing literature favors the use of anti-viral therapy with immunosuppressive agents without the concern of worsening infection [2].","PeriodicalId":23169,"journal":{"name":"TP100. TP100 UNEXPECTED COVID-19 CASE REPORTS","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pauci Immune Glomerulonephritis; A Late Complication of COVID-19 Infection\",\"authors\":\"H. Waseem, F. Zafar, M. Anser, M. Zia\",\"doi\":\"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A4089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Coronavirus disease is a multi-organ disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2). Although acute kidney injury, collapsing glomerulopathy and thrombotic micro-angiopathy have been frequently attributed to COVID-19, pauci-immune glomerulonephritis (GN) has rarely been described [1]. Here we report a case of pauci-immune GN associated with SARS-CoV-2. Case Presentation: A 53 years old female with hypertension, diabetes mellitus, hepatitis C (treated 6 years ago), and recent covid-19 pneumonia (3 months ago), presented with dysuria, nausea, and vomiting. She denied fever, flank pain, and hematuria. The laboratory workup showed elevated blood urea nitrogen BUN 82 mg/dl and creatinine Cr 9.8 mg/dl (baseline creatinine was 0.9 mg/dl three months ago). Urinalysis showed proteinuria >1000 mg/dl and urine protein creatinine ratio of 5.3 (normal < 0.1), concerning for glomerulonephritis. Serological evaluation for glomerular disease showed normal complements C3 and C4, normal titers of anti-neutrophil cytoplasmic antibodies including p-ANCA, c-ANCA, atypical ANCA, and cryoglobulins. Screening for Hepatitis B and Hepatitis C was negative. The remainder of the autoimmune workup was unremarkable including Rheumatoid factor, Anti CCP antibodies (Ab), Anti Ribo-nucleoprotein Ab, and Anti Glomerular basement membrane antibodies. Coronavirus PCR was negative and qualitative IgG was reactive. CT chest showed idiopathic pulmonary fibrosis (IPF) and resolving ground glass opacities from prior coronavirus infection. CT abdomen and pelvis was unremarkable for obstructive uropathy. The renal biopsy showed pauci-immune focal sclerosis with 20% fibro-cellular crescents diagnostic for pauci-immune glomerulonephritis. The patient was treated for pauci-immune glomerulonephritis with pulse-dose intravenous steroids (methylprednisolone) followed by oral prednisone and rituximab. The renal functions improved dramatically (on day 15, her creatinine down-trended to 4 mg/dl from 9mg/dl on admission). She did not require intermittent hemodialysis and was discharged on day 15 with outpatient follow up. Discussion: The mechanisms of acute kidney injury in COVID-19 include renal hypoperfusion, endothelial dysfunction, micro-thrombi, and cytopathic effects of SARS-CoV-2 towards renal tubules and glomeruli. Due to a lack of scientific evidence related to coronavirus disease, the management of glomerulopathy is challenging. The existing literature favors the use of anti-viral therapy with immunosuppressive agents without the concern of worsening infection [2].\",\"PeriodicalId\":23169,\"journal\":{\"name\":\"TP100. TP100 UNEXPECTED COVID-19 CASE REPORTS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"TP100. TP100 UNEXPECTED COVID-19 CASE REPORTS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A4089\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP100. TP100 UNEXPECTED COVID-19 CASE REPORTS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A4089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

简介:冠状病毒病是由严重急性呼吸系统综合征冠状病毒2型(SARS- CoV-2)引起的多器官疾病。虽然急性肾损伤、衰竭肾小球病和血栓性微血管病经常被归因于COVID-19,但缺乏免疫肾小球肾炎(GN)很少被描述[1]。在这里,我们报告一例与SARS-CoV-2相关的缺乏免疫的GN。病例介绍:女性,53岁,患有高血压、糖尿病、丙型肝炎(6年前治疗),新近感染covid-19肺炎(3个月前),表现为排尿困难、恶心、呕吐。她否认发烧、腹部疼痛和血尿。实验室检查显示血尿素氮BUN升高82 mg/dl,肌酐Cr升高9.8 mg/dl(三个月前基线肌酐为0.9 mg/dl)。尿分析显示蛋白尿1000 mg/dl,尿蛋白肌酐比值5.3(正常;0.1),与肾小球肾炎有关。肾小球疾病的血清学评估显示补体C3和C4正常,抗中性粒细胞细胞质抗体包括p-ANCA、c-ANCA、非典型ANCA和冷球蛋白滴度正常。乙型和丙型肝炎筛查呈阴性。其余自身免疫检查包括类风湿因子、抗CCP抗体(Ab)、抗核蛋白抗体和抗肾小球基底膜抗体均无显著差异。冠状病毒PCR阴性,定性IgG阳性。胸部CT显示特发性肺纤维化(IPF),并解决了先前冠状病毒感染引起的磨玻璃影。腹部及骨盆CT对梗阻性尿路病变表现不明显。肾活检显示包囊免疫局灶性硬化伴20%纤维细胞月牙征,诊断为包囊免疫肾小球肾炎。患者接受脉冲剂量静脉注射类固醇(甲基强的松龙)治疗,随后口服强的松和利妥昔单抗。肾功能显著改善(第15天,她的肌酐从入院时的9mg/dl下降到4mg /dl)。患者不需要间歇血液透析,于第15天出院,门诊随访。讨论:COVID-19急性肾损伤的机制包括肾灌注不足、内皮功能障碍、微血栓和SARS-CoV-2对肾小管和肾小球的细胞病变作用。由于缺乏与冠状病毒疾病相关的科学证据,肾小球病变的管理具有挑战性。现有文献倾向于使用免疫抑制剂联合抗病毒治疗而不担心加重感染[2]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Pauci Immune Glomerulonephritis; A Late Complication of COVID-19 Infection
Introduction: Coronavirus disease is a multi-organ disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2). Although acute kidney injury, collapsing glomerulopathy and thrombotic micro-angiopathy have been frequently attributed to COVID-19, pauci-immune glomerulonephritis (GN) has rarely been described [1]. Here we report a case of pauci-immune GN associated with SARS-CoV-2. Case Presentation: A 53 years old female with hypertension, diabetes mellitus, hepatitis C (treated 6 years ago), and recent covid-19 pneumonia (3 months ago), presented with dysuria, nausea, and vomiting. She denied fever, flank pain, and hematuria. The laboratory workup showed elevated blood urea nitrogen BUN 82 mg/dl and creatinine Cr 9.8 mg/dl (baseline creatinine was 0.9 mg/dl three months ago). Urinalysis showed proteinuria >1000 mg/dl and urine protein creatinine ratio of 5.3 (normal < 0.1), concerning for glomerulonephritis. Serological evaluation for glomerular disease showed normal complements C3 and C4, normal titers of anti-neutrophil cytoplasmic antibodies including p-ANCA, c-ANCA, atypical ANCA, and cryoglobulins. Screening for Hepatitis B and Hepatitis C was negative. The remainder of the autoimmune workup was unremarkable including Rheumatoid factor, Anti CCP antibodies (Ab), Anti Ribo-nucleoprotein Ab, and Anti Glomerular basement membrane antibodies. Coronavirus PCR was negative and qualitative IgG was reactive. CT chest showed idiopathic pulmonary fibrosis (IPF) and resolving ground glass opacities from prior coronavirus infection. CT abdomen and pelvis was unremarkable for obstructive uropathy. The renal biopsy showed pauci-immune focal sclerosis with 20% fibro-cellular crescents diagnostic for pauci-immune glomerulonephritis. The patient was treated for pauci-immune glomerulonephritis with pulse-dose intravenous steroids (methylprednisolone) followed by oral prednisone and rituximab. The renal functions improved dramatically (on day 15, her creatinine down-trended to 4 mg/dl from 9mg/dl on admission). She did not require intermittent hemodialysis and was discharged on day 15 with outpatient follow up. Discussion: The mechanisms of acute kidney injury in COVID-19 include renal hypoperfusion, endothelial dysfunction, micro-thrombi, and cytopathic effects of SARS-CoV-2 towards renal tubules and glomeruli. Due to a lack of scientific evidence related to coronavirus disease, the management of glomerulopathy is challenging. The existing literature favors the use of anti-viral therapy with immunosuppressive agents without the concern of worsening infection [2].
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The global race to vaccinate Covid-19 vaccine production and tariffs on vaccine inputs Indicative list of trade-related bottlenecks and trade-facilitating measures on critical products to combat covid-19 Joint Indicative List of Critical COVID-19 Vaccine Inputs for Consultation Improving trade data for products essential to fight covid-19
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1